PrECOG: Added everolimus extends PFS for HR positive, HER2 negative breast cancer

Share :
Published: 7 Dec 2016
Views: 2243
Rating:
Save
Dr Noah Kornblum - Montefiore Medical Center, New York, USA

Dr Kornblum presents results at the San Antonio Breast Cancer Symposium 2016 from a randomised, double-blind phase II trial of everolimus vs placebo in combination with fulvestrant from HR /HER- metastatic breast cancer for patients resistant of aromatase inhibitor therapy.

The addition of everolimus doubled median PFS to 10.4 months, with adverse events at a higher, but manageable, severity, consistent with previous assessment of everolimus in the BOLERO-2 trial.